Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
Poonam P, Koscik R, Nguyen T, Rikhi S, Lin H. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19. PLOS ONE 2022, 17: e0270646. PMID: 35759496, PMCID: PMC9236233, DOI: 10.1371/journal.pone.0270646.Peer-Reviewed Original ResearchConceptsInhaled Nitric OxideInhaled epoprostenolVentilator free daysMechanically Ventilated PatientsP/F ratioRefractory hypoxemiaInitiation of pulmonary vasodilator therapyCohort of mechanically ventilated patientsInhaled nitric oxide groupDuration of mechanical ventilationDays to extubationPulmonary vasodilator therapySeverity of ARDSNitric oxideIn-Hospital MortalityDays of treatmentFree daysPulmonary vasodilationVasodilator therapyNo significant differenceProspective studyCOVID-19 infectionMechanical ventilationDay 1Primary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply